Literature DB >> 18430993

Multiple SNPs within and surrounding the apolipoprotein E gene influence cerebrospinal fluid apolipoprotein E protein levels.

Lynn M Bekris1, Steven P Millard, Nichole M Galloway, Simona Vuletic, John J Albers, Ge Li, Douglas R Galasko, Charles DeCarli, Martin R Farlow, Chris M Clark, Joseph F Quinn, Jeffrey A Kaye, Gerard D Schellenberg, Debby Tsuang, Elaine R Peskind, Chang-En Yu.   

Abstract

The epsilon4 allele of the apolipoprotein E gene (APOE) is associated with increased risk and earlier age at onset in late onset Alzheimer's disease (AD). Other factors, such as expression level of apolipoprotein E protein (apoE), have been postulated to modify the APOE related risk of developing AD. Multiple loci in and outside of APOE are associated with a high risk of AD. The aim of this exploratory hypothesis generating investigation was to determine if some of these loci predict cerebrospinal fluid (CSF) apoE levels in healthy non-demented subjects. CSF apoE levels were measured from healthy non-demented subjects 21-87 years of age (n=134). Backward regression models were used to evaluate the influence of 21 SNPs, within and surrounding APOE, on CSF apoE levels while taking into account age, gender, APOE epsilon4 and correlation between SNPs (linkage disequilibrium). APOE epsilon4 genotype does not predict CSF apoE levels. Three SNPs within the TOMM40 gene, one APOE promoter SNP and two SNPs within distal APOE enhancer elements (ME1 and BCR) predict CSF apoE levels. Further investigation of the genetic influence of these loci on apoE expression levels in the central nervous system is likely to provide new insight into apoE regulation as well as AD pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18430993      PMCID: PMC3192652          DOI: 10.3233/jad-2008-13303

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  45 in total

1.  Simultaneous effects of the apolipoprotein E polymorphism on apolipoprotein E, apolipoprotein B, and cholesterol metabolism.

Authors:  E Boerwinkle; G Utermann
Journal:  Am J Hum Genet       Date:  1988-01       Impact factor: 11.025

2.  The -491AA polymorphism in the APOE gene is associated with increased plasma apoE levels in Alzheimer's disease.

Authors:  S M Laws; K Taddei; G Martins; A Paton; C Fisher; R Clarnette; J Hallmayer; W S Brooks; S E Gandy; R N Martins
Journal:  Neuroreport       Date:  1999-03-17       Impact factor: 1.837

Review 3.  Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease.

Authors:  Robert W Mahley; Karl H Weisgraber; Yadong Huang
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-27       Impact factor: 11.205

4.  Epidemiological, clinical, and neuropathological study of apolipoprotein E genotype in Alzheimer's disease.

Authors:  B T Hyman; T Gomez-Isla; G W Rebeck; M Briggs; H Chung; H L West; S Greenberg; S Mui; S Nichols; R Wallace; J H Growdon
Journal:  Ann N Y Acad Sci       Date:  1996-12-16       Impact factor: 5.691

5.  Detection of apolipoprotein E/dimeric soluble amyloid beta complexes in Alzheimer's disease brain supernatants.

Authors:  B Permanne; C Perez; C Soto; B Frangione; T Wisniewski
Journal:  Biochem Biophys Res Commun       Date:  1997-11-26       Impact factor: 3.575

6.  SNPing away at complex diseases: analysis of single-nucleotide polymorphisms around APOE in Alzheimer disease.

Authors:  E R Martin; E H Lai; J R Gilbert; A R Rogala; A J Afshari; J Riley; K L Finch; J F Stevens; K J Livak; B D Slotterbeck; S H Slifer; L L Warren; P M Conneally; D E Schmechel; I Purvis; M A Pericak-Vance; A D Roses; J M Vance
Journal:  Am J Hum Genet       Date:  2000-06-21       Impact factor: 11.025

7.  A polymorphism in the regulatory region of APOE associated with risk for Alzheimer's dementia.

Authors:  M J Bullido; M J Artiga; M Recuero; I Sastre; M A García; J Aldudo; C Lendon; S W Han; J C Morris; A Frank; J Vázquez; A Goate; F Valdivieso
Journal:  Nat Genet       Date:  1998-01       Impact factor: 38.330

8.  Cerebrospinal fluid apolipoprotein E is reduced in Alzheimer's disease.

Authors:  K Blennow; C Hesse; P Fredman
Journal:  Neuroreport       Date:  1994-12-20       Impact factor: 1.837

9.  Reduced levels of cholesterol, phospholipids, and fatty acids in cerebrospinal fluid of Alzheimer disease patients are not related to apolipoprotein E4.

Authors:  M Mulder; R Ravid; D F Swaab; E R de Kloet; E D Haasdijk; J Julk; J J van der Boom; L M Havekes
Journal:  Alzheimer Dis Assoc Disord       Date:  1998-09       Impact factor: 2.703

10.  Apolipoprotein E4 decreases whereas apolipoprotein E3 increases the level of secreted amyloid precursor protein after closed head injury.

Authors:  Y Ezra; L Oron; L Moskovich; A D Roses; S M Beni; E Shohami; D M Michaelson
Journal:  Neuroscience       Date:  2003       Impact factor: 3.590

View more
  46 in total

Review 1.  The Alzheimer's disease mitochondrial cascade hypothesis.

Authors:  Russell H Swerdlow; Jeffrey M Burns; Shaharyar M Khan
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

2.  Amyloid precursor protein (APP) processing genes and cerebrospinal fluid APP cleavage product levels in Alzheimer's disease.

Authors:  L M Bekris; N M Galloway; S Millard; D Lockhart; G Li; D R Galasko; M R Farlow; C M Clark; J F Quinn; J A Kaye; G D Schellenberg; J B Leverenz; P Seubert; D W Tsuang; E R Peskind; C E Yu
Journal:  Neurobiol Aging       Date:  2010-12-31       Impact factor: 4.673

3.  ALS-linked mutant superoxide dismutase 1 (SOD1) alters mitochondrial protein composition and decreases protein import.

Authors:  Quan Li; Christine Vande Velde; Adrian Israelson; Jing Xie; Aaron O Bailey; Meng-Qui Dong; Seung-Joo Chun; Tamal Roy; Leah Winer; John R Yates; Roderick A Capaldi; Don W Cleveland; Timothy M Miller
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-15       Impact factor: 11.205

4.  Association of cerebrospinal fluid Aβ42 with A2M gene in cognitively normal subjects.

Authors:  Steven P Millard; Franziska Lutz; Ge Li; Douglas R Galasko; Martin R Farlow; Joseph F Quinn; Jeffrey A Kaye; James B Leverenz; Debby Tsuang; Chang-En Yu; Elaine R Peskind; Lynn M Bekris
Journal:  Neurobiol Aging       Date:  2013-09-04       Impact factor: 4.673

5.  A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer's disease.

Authors:  A D Roses; M W Lutz; H Amrine-Madsen; A M Saunders; D G Crenshaw; S S Sundseth; M J Huentelman; K A Welsh-Bohmer; E M Reiman
Journal:  Pharmacogenomics J       Date:  2009-12-22       Impact factor: 3.550

6.  Gene sequences regulating the production of apoE and cerebral palsy of variable severity.

Authors:  Espen Lien; Guro L Andersen; Yongde Bao; Heather Gordish-Dressman; Jon Skranes; James A Blackman; Torstein Vik
Journal:  Eur J Paediatr Neurol       Date:  2014-04-18       Impact factor: 3.140

7.  Alzheimer's disease: diagnostics, prognostics and the road to prevention.

Authors:  Iris Grossman; Michael W Lutz; Donna G Crenshaw; Ann M Saunders; Daniel K Burns; Allen D Roses
Journal:  EPMA J       Date:  2010-06-29       Impact factor: 6.543

Review 8.  Mitochondrial trafficking of APP and alpha synuclein: Relevance to mitochondrial dysfunction in Alzheimer's and Parkinson's diseases.

Authors:  Latha Devi; Hindupur K Anandatheerthavarada
Journal:  Biochim Biophys Acta       Date:  2009-07-18

9.  Association of TOMM40 polymorphisms with late-onset Alzheimer's disease in a Northern Han Chinese population.

Authors:  Xiao-Ying Ma; Jin-Tai Yu; Wei Wang; Hui-Fu Wang; Qiu-Yan Liu; Wei Zhang; Lan Tan
Journal:  Neuromolecular Med       Date:  2013-01-04       Impact factor: 3.843

10.  Cerebrospinal fluid concentration of brain-derived neurotrophic factor and cognitive function in non-demented subjects.

Authors:  Ge Li; Elaine R Peskind; Steven P Millard; Peter Chi; Izabela Sokal; Chang-En Yu; Lynn M Bekris; Murray A Raskind; Douglas R Galasko; Thomas J Montine
Journal:  PLoS One       Date:  2009-05-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.